Q-omics provides the consensus-scored MIR4671 profile across patient tissues and cancer cell-line models. MIR4671 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MIR4671 is differentially expressed in 6, with the highest sampling consensus in LUSC. Additionally, MIR4671 RNA expression shows 11,489 significant gene co-expression associations, with the highest sampling consensus in LIHC. Together, these results highlight MESO, LUSC, and LIHC as cancer lineages where MIR4671 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR4671 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR4671 survival associations across molecular data types. MIR4671 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR4671 RNA expression–survival associations across cancer types. High MIR4671 expression shows unfavorable associations in MESO, STAD, TGCT, KIRP and KIRC, but favorable associations in UCS. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for MIR4671 RNA expression.
This table summarizes MIR4671 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR4671. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR4671 shows lower tumor expression in BRCA and higher tumor expression in LUSC, HNSC, KICH, THCA and CHOL. The LUSC box plot shows higher MIR4671 RNA expression in tumor versus normal tissue (log2 FC = +0.472, t-test p < 0.001).
This table shows molecular features associated with MIR4671 in patient tissues and cancer cell lines. In patient samples, MIR4671 shows the broadest associations at the RNA and protein expression levels, with LIHC recurring as the lineage with the largest associated feature set.
